Ignite Creation Date:
2024-05-06 @ 8:43 AM
Last Modification Date:
2024-10-26 @ 12:04 PM
Study NCT ID:
NCT02802163
Status:
WITHDRAWN
Last Update Posted:
2017-04-25
First Post:
2016-06-13
Brief Title:
Induction Therapy for Multiple Myeloma With Carfilzomib LenalidomideDexamethasonePanobinostat
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
Phase I-II Study of Carfilzomib Lenalidomide Dexamethasone and Panobinostat Ca-R-Pa-Diem as Induction Therapy for Newly Diagnosed Untreated Transplant-Eligible Multiple Myeloma Patients
Status:
WITHDRAWN
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
study drug unavailable
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study for Phase l is to determine the maximum tolerated dose of panobinostat given in combination with carfilzomib lenalidomide and dexamethasone in 28-day cycles as induction initial therapy to participants with newly diagnosed multiple myeloma
In Phase ll investigators will evaluate the safety side effects and efficacy effectiveness of panobinostat in combination with carfilzomib lenalidomide and dexamethasone
In Phase ll investigators will evaluate the safety side effects and efficacy effectiveness of panobinostat in combination with carfilzomib lenalidomide and dexamethasone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None